DaVita Inc. with ticker code (DVA) now have 8 analysts in total covering the stock. The consensus rating is ‘Hold’. The target price ranges between 150 and 112 with the average target price sitting at 126. Now with the previous closing price of 109.39 this would indicate that there is a potential upside of 15.2%. The 50 day MA is 106.94 and the 200 moving average now moves to 117. The market capitalisation for the company is $11,283m. Visit the company website at: https://www.davita.com
The potential market cap would be $12,997m based on the market concensus.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
